Plus   Neg

CymaBay Therapeutics Inc. (CBAY) Has Surged To A New High On Study Results

CymaBay Therapeutics Inc. (CBAY) reported positive results from its Phase 2 study of seladelpar in patients with primary biliary cholangitis Monday morning.

CymaBay Therapeutics gapped open sharply higher this morning and is now up 1.70 at $7.35 with volume at over a 6-month high. The stock has broken out of a 3-week trading range and has set a new high for the year.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Follow RTT